EUCTR2008-007153-13-IT进行中（未招募）不适用
An open label, single arm, phase II study of combination RAD001 and octreotide LAR in patients with advanced neuroendocrine tumors as first line treatment - RAD001 and NETs, first line treatment
I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY0 个研究点开始时间: 2009年4月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Histological diagnosis of well differentiated endocrine carcinoma or histological diagnosis of typical and atypical carcinoid of the lung
- •- Ki-67 ≤ 2%.
- •- Metastatic or locally advanced disease
- •- Adult male or female patients ≥18 years of age
- •- Patients with or without carcinoid syndrome
- •- Adequate renal function: serum creatinine ≤1.5 x ULN
- •- Adequate liver function as shown by: serum bilirubin ≤1.5 x ULN; ALT and AST <= 2.5x ULN (<= 5x ULN in patients with liver metastases)
- •- Adequate bone marrow function: ANC >= 1.5 x 109/L;PLT >= 100 x 109/L; Hb > 9 g/dL
- •- ECOG performance status 0-1
- •- Life expectancy >6 months
- •- At least one measurable lesion at CT scan as defined by RECIST
- •- Women of childbearing potential must have had a negative serum or urine pregnancy test within 7 days prior to the administration of the study treatment start, and must use an acceptable form of contraception.
- •- Patients who give a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients who received prior therapy with somatostatin analogues, RAD001 or other rapamycins
- •- Patients who received a prior anticancer therapy for neuroendocrine tumor
- •- Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients
- •- Histological diagnosis of poorly differentiated endocrine carcinoma
- •- Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as: unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia; severely impaired lung function; uncontrolled diabetes; any active (acute or chronic) or uncontrolled infection/disorders that impair the ability to evaluate the patient or for the patient to complete the study; non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with this study treatment, such as severe hypertension that is not controlled with medical management and thyroid abnormalities due to which thyroid function cannot be maintained in the normal range by medication; liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis or chronic persistent hepatitis; fatal or life-threatening autoimmune and ischemic disorders; uncontrolled hyperlipidemia
- •- Patients with serious neurological or psychiatric disorders
- •- Patients with central nervous system (CNS) metastases
- •- Patients who have a history of another primary malignancy with the exception of basal or squamous cell skin cancer, in situ cancer, and any cancer from which the patient has been disease free for 5 years
- •- Immunocompromised patients, including positive HIV test. An HIV test is not required to enter the study
- •- Patients on concomitant medications known to inhibit, induce or be a substrate of CYP3A isoenzyme
- •- Female patients who are pregnant or breast feeding
- •- Patients of reproductivepotential who are not using appropriate contraceptive methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Oral contraceptives are not accetable
研究者
相似试验
进行中（未招募）
不适用
A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancerEpithelial ovarian cancer, fallopian tube or primary peritoneal carcinomaMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10016180Term: Fallopian tube cancerMedDRA version: 9.1Level: LLTClassification code 10061344Term: Peritoneal neoplasmEUCTR2008-008336-85-NLF. Hoffmann-La Roche Ltd.180
进行中（未招募）
1 期
A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer - OCTAVIAEUCTR2008-008336-85-FRF. Hoffmann-La Roche Ltd.189
尚未招募
2 期
To evaluate the efficacy of satapuspha choornam and tila kashayam in PCOSCTRI/2022/09/045593Dr Gulnar Mariam M
进行中（未招募）
1 期
A study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant)with or without a short course of chemotherapy with paclitaxel in patients withunresectable locally advanced or metastatic breast cancer with aggressive disease criteria.Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease criteria.MedDRA version: 21.1Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864EUCTR2020-001648-24-ITMEDICA SCIENTIA INNOVATION RESEARCH S.L.160
进行中（未招募）
3 期
Clinical study on healing of Radius fracture by combined use of Murivenna and Trayodashanga guggulu along with posterior slabCTRI/2018/04/013059Amrita School of Ayurveda